The Abu Dhabi Public Health Centre (ADPHC), in collaboration with M42, has launched a non-invasive blood-based cancer screening method for colorectal cancer, known as liquid biopsy. This innovative test is instrumental in assessing cancer risk and identifying early signs of tumours or precancerous growths in the colon. However, it does not substitute the traditional colonoscopy, which remains the gold standard for diagnosing colorectal cancer.
The liquid biopsy will be integrated into the comprehensive health screening program (Ifhas) and will be accessible at major healthcare facilities managed by Ambulatory Healthcare Services (AHS) and M42 across Abu Dhabi, Al Ain, and the Al Dhafra region.
Dr. Ahmed AlKhazraji, Acting Director General of ADPHC, emphasized, "Abu Dhabi is making significant strides in prioritizing public health by advancing early cancer detection. The introduction of a non-invasive and innovative test like liquid biopsy offers a more accessible and comfortable screening alternative for patients, thereby lowering barriers and encouraging more individuals to participate in regular screenings."
Dr. Fahed Al Marzooqi, Deputy COO of M42, added, "This initiative will bolster early detection rates for colorectal cancer in Abu Dhabi and address one of the primary causes of cancer-related fatalities. By providing a more accessible and non-invasive screening option, we aim to enhance participation rates and improve outcomes, ultimately contributing to a healthier future for the UAE population."
Regular screening is the most effective approach to preventing colorectal cancer and improving survival rates. The Department of Health in Abu Dhabi advises routine colorectal cancer screening for all men and women aged 40 and above. Colorectal cancer ranks as the third most prevalent cancer type in Abu Dhabi, with a higher incidence among males. Data from 2023 indicates that 67% of new colorectal cancer cases in Abu Dhabi were diagnosed at an advanced stage, negatively impacting health outcomes and reducing survival rates. The introduction of the liquid biopsy test marks a substantial advancement in enhancing screening participation, early detection, and overall outcomes for the community.
Source link: https://www.khaleejtimes.com
